Cellectis (NASDAQ:CLLS) Upgraded by Barclays to Strong-Buy Rating

Posted by Francis Steltz on May 29th, 2026

Cellectis (NASDAQ:CLLS – Get Free Report) was upgraded by investment analysts at Barclays to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other equities analysts have also recently issued reports on CLLS. Citizens Jmp reiterated a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a report on Tuesday, April 14th. Jefferies Financial Group assumed coverage on Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $7.00.

Read Our Latest Stock Report on Cellectis

Cellectis Price Performance

NASDAQ:CLLS opened at $3.63 on Thursday. The stock’s fifty day moving average price is $3.70 and its two-hundred day moving average price is $4.03. Cellectis has a 52-week low of $1.33 and a 52-week high of $5.48. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52. The company has a market cap of $364.23 million, a price-to-earnings ratio of -5.42 and a beta of 2.94.

Cellectis (NASDAQ:CLLS – Get Free Report) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.08. The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Lido Advisors LLC bought a new position in shares of Cellectis in the 1st quarter worth $32,000. Marshall Wace LLP grew its stake in shares of Cellectis by 1,610.3% during the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 168,038 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Cellectis in the fourth quarter valued at about $15,385,000. Global Retirement Partners LLC bought a new stake in Cellectis in the fourth quarter valued at about $34,000. Finally, Millennium Management LLC lifted its stake in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

(Get Free Report)

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.